The medicinal chemist's toolbox: How to use it to develop small molecule CK2 inhibitors

Marc Le Borgne
Université Lyon, France

Protein kinase CK2 is a ubiquitous eukaryotic serine/threonine protein kinase. CK2 is a highly pleiotropic enzyme which catalyzes the transfer of terminal phosphate from ATP or GTP to various proteins implicated in a wide variety of cell functions. The catalytic subunits of CK2 (alpha and/or alpha') are constitutively active either alone or in combination with the regulatory beta-subunits to give a heterotetrameric protein. Overexpression of CK2 creates a favorable environment for tumor development. CK2 has now emerged as a relevant therapeutic target for the treatment of cancer (e.g. prostate cancer, breast cancer, hematological malignancies, PDAC) and diverse strategies are developed to target CK2, and to synthesize specific, selective and cell-permeable inhibitors. My talk would like to present a fully integrated Drug Discovery presentation on the first protein kinase discovered in 1954. CK2 is a remarkable target to promote Drug Discovery Chemistry. After nearly 60 years, CK2 is still a challenge for chemists! They must design small molecules to inhibit CK2 holoenzyme or its catalytic subunits; large chemical diversity is then required! Furthermore the success will depend on how chemists interfere with biologists. Both must investigate in all areas at the interface of chemistry and biology…

Biography
Marc Le Borgne has completed his PhD from Nantes Atlantic University after Pharmacy studies (6 years). He is the director of EA 4446 B2C, a research group dedicated to Drug Design and Structural Optimization. He has published more than 61 papers in reputed journals and has been serving as an Editorial Board Member of Journal of Enzyme Inhibition and Medicinal Chemistry (2009-2012) and Current Bioactive Compounds (2008-). He gave some invited lectures abroad (Saarbrück, Oslo, Tromsø, Bergen, Debrecen, Sacramento, Helsinki, Oulu…). He is developing bioactive small molecules (e.g. kinases and CYP inhibitors).

marc.le-borgne@univ-lyon1.fr

Notes: